

FIG. 1 A: Full length Apo-A1 sequence

1
MKA AVL TLAVL FLTGSQARHFWQQDEPPQSPWDRVKDLATVYVD

VLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKE

TEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHE

194
LQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELQRRLAARLEALKENGGARLA EYHA

267
KATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ

sig_peptide 20..91

mature_protein 92..820

20 a tgaagctgc ggtgctgacc ttggcctgc tcttctgac
61 ggggagccag gctcggcatt tctggcagca agatgaaccc cccagagcc cctgggatcg
121 agtgaaggac ctggccactg tgtactgga tgtgctcaa gacagcggca gagactatgt
181 gtcccagttt gaaggtccg ccttgggaaa acagctaac ctaagctcc ttgacaactg
241 ggacagcgtg acctccacct tcagcaagct gcgcgaacag ctggccctg tgaccaggga
301 gttctgggat aacctggaaa aggagacaga gggcctgagg caggagatga gcaaggatct
361 ggaggagggtg aaggccaagg tgcagcccta cctggacgac ttccagaaga agtggcagga
421 ggagatggag ctctaccgcc agaaggtgga gccgctgcgc gcagagctcc aagagggcgc
481 gcgccagaag ctgcacgagc tgcaagagaa gctgagccca ctgggcgagg agatgcgcga
541 ccgcgcgcgc gcccatgtgg acgcgtgcg cagcatctg gcccctaca gcgacgagct
601 gcgccagcgc ttggccgcgc gccttgagge tctcaaggag aacggcggcg ccagactggc
661 cgagtaccac gccaaaggcca ccgagcatct gacacgctc agcgagaagg ccaagcccgc
721 gctcgaggac ctccgccaag gcctgtgccc cgtgtggag agcttcaagg tcagcttct
781 gagcgtctc gaggagtaca ctaagaagct caacaccag

[illegible]

25

VLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKE
TEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHE
LOEKLSPIDGEEMRDRARAHVDALRTHLAPYSDEL

92 gatgaacc cccagagcc cctgggatcg

121 agtgaaggac ctggccactg tgtacgtgga tgtgtctaaa gacagcggca gagactatgt

181 gtcccagttt gaaggctcgg ccttgggaaa acagctaaac ctaangctcc ttgacaactg

241 ggacagcgtg acctccacct tcagcaagct gcgcgaacag ctgcggccctg tgaccacgga

301 gttctgggat aacctggaaa aggagacaga ggcctgagg caggagatga gcaaggatct

361 ggaggaggtg aaggccaagg tgcagcccta cctggacgac ttccagaaga agtggcagga

421 ggagatggag ctctaccgcc agaaggtgga gccgtgcgc gcagagctcc aagagggcgc

481 ggcgcagaag ctgcacgagc tgcaagagaa gctgagccca ctgggcgagg agatgcgcga

541 ccgcgcgcgc gcccatgtgg acgcgtgcg cagcatctg gcccctaca gcgacgagct

601 g

FIG. 1 C

13K N-terminal fragment --

25

DEPPQSPWDRVKDLATVYVD

VLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKE

144

TEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVE

92 gatgaacce cccagagcc cctgggatcg

121 agtgaaggac ctggeccactg tgtactgga tgtgtcaaa gacagegga gagactatgt

181 gtcccagttt gaaggctccg ccttgggaaa acagctaaac ctaaagctcc ttgacaactg

241 ggacagcgtg acctccacct tcagcaagct gcgcgaacag ctgggeectg tgaccaggga

301 gttctgggat aacctggaaa aggagacaga gggcctgagg caggagatga gcaaggatct

361 ggaggaggty aaggccaagg tgcageecta cctggacgac ttccagaaga agtggcagga

421 ggagatggag ctctaccgcc agaaggtaga g

1000 900 800 700 600 500 400 300 200 100 0

FIG. 1 D

13 K C-terminal fragment.

156

QKLHE

194

LQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELQRQLAARLEALKENG GARLA EYHA

267

KATEHLSTLSEKAKPALEDLRQG L L P V L E S F K V S F L S A L E E Y T K K L N T Q

485 cagaag ctgcacgagc tgcaagagaa gctgagccca ctgggcgagg agatgcgcga

541 ccgcgcgcgc gcccatgttg acgcgtgcg cagcatctg gcccctaca gcgacgagct

601 gcgcgcgcgc ttggccgcgc gcttgagge tctcaaggag aacggcgcg ccagactgce

661 cgagtaccac gccaaagcca ccgagcatct gacacgctc agcgagaagg ccaagcccgc

721 gctcgaggac ctcgcgaag gctgtctgce cgtgctggag agcttcaagg tcagcttct

781 gacgctctc gaggagtaca ctaagaagct caacaccag

156
QKLHE
194
LQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELQRQLAARLEALKENG GARLA EYHA
267
KATEHLSTLSEKAKPALEDLRQG L L P V L E S F K V S F L S A L E E Y T K K L N T Q
485 cagaag ctgcacgagc tgcaagagaa gctgagccca ctgggcgagg agatgcgcga
541 ccgcgcgcgc gcccatgttg acgcgtgcg cagcatctg gcccctaca gcgacgagct
601 gcgcgcgcgc ttggccgcgc gcttgagge tctcaaggag aacggcgcg ccagactgce
661 cgagtaccac gccaaagcca ccgagcatct gacacgctc agcgagaagg ccaagcccgc
721 gctcgaggac ctcgcgaag gctgtctgce cgtgctggag agcttcaagg tcagcttct
781 gacgctctc gaggagtaca ctaagaagct caacaccag

Fig. 2




Fig. 3




Fig. 4





Fig. 5




Fig. 6




Fig. 8




Fig. 9




Fig. 10


IL-1 β (pg/ml)[illegible]

Fig. 11




Fig. 11 shows the effect of various treatments on IL-1 β and TNF- α levels. The treatments include Medium, HUTs, HUTs + HS (10%), HUTs + Apo A-I (100 μ g/ml), HUTs + Apo A-II (100 μ g/ml), and HUTs + DII/DIII (50 μ g/ml). The y-axis represents the concentration in pg/ml. Error bars are shown for the HUTs and HUTs + HS (10%) treatments.